Absorption and Distribution of Glucosamine and Chondroitin

The purpose of this study is to examine the way the dietary supplements glucosamine and chondroitin are absorbed and distributed throughout the body.

Official Title

A Pharmacokinetic Study of Glucosamine and Chondroitin

Conditions

Osteoarthritis

Study Type

Interventional

Study Design

Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study

Further Details

Osteoarthritis is the most common musculoskeletal disease in the world. While predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. Traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. The use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. This study will examine the pharmacokinetics of glucosamine and chondroitin.This study consists of two phases. In Phase I, participants will have two study visits, during which multiple blood samples will be taken in order to determine levels of glucosamine and chondroitin found naturally in the body. During Phase II, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. Blood samples will be taken at each of the three Phase II study visits to examine the pharmacokinetics of glucosmaine and chondroitin.

Study Start

Eligibility & Criteria

Ages Eligible for Study: 21 Years and above, Genders Eligible for Study: BothAccepts Healthy VolunteersCriteriaInclusion Criteria: * Able to walkExclusion Criteria: * Allergy to glucosamine, chondroitin, or shellfish * Liver or kidney disease * Diabetes mellitus * Concurrent use of other complementary or alternative therapies

Total Enrolment

70

Contact Details

[1] University of Utah Health Sciences Center, Salt Lake City, Utah,Contact Details: – Kalli Cooper 801-581-7724 (US Phone Number) – Christopher G. Jackson, MD, Principal Investigator